---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-043040"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2023-02-21T23:59:59+00:00"
generated_at: "2026-06-19T07:03:55.865550+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Verrica prices $32.5M underwritten offering of common stock and pre-funded warrants

## Summary
- 750,000 shares at $6.75 and 4,064,814 pre-funded warrants at $6.7499 per share.
- Gross proceeds expected ~$32.5M before underwriting discounts and expenses.
- Jefferies LLC acting as sole book-runner; closing expected Feb 23, 2023.
- Offering substantially led by one healthcare dedicated fund.
- Shelf registration statement (333-268229) effective Dec 19, 2022.

## SEC filing metadata
- accession: 0001193125-23-043040
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2023-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312523043040/0001193125-23-043040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312523043040/d464394d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-043040
- JSON: https://secwatch.observer/filing/0001193125-23-043040.json
- Plain text: https://secwatch.observer/filing/0001193125-23-043040.txt

## Key facts
- Material Agreements
  Verrica Pharmaceuticals Inc. entered into Underwriting Agreement with Jefferies LLC valued at approximately $32.5 million (effective 2023-02-21).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Jefferies LLC
  - Value: approximately $32.5 million
  - Effective: 2023-02-21
  source text: On February 21, 2023, Verrica Pharmaceuticals Inc. (the “C ompan y’) entered into an underwriting agreement (“ Underwriting Agreement ”) with Jefferies LLC (the “ Underwriter ”), to issue and sell 750,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”) at a price of $6.75 per share and, in lieu of Common Stock, certain investors were issued pre-funded warrants to purchase an aggregate of 4,064,814 shares of Common Stock at a price of $6.7499 (the “ Pre-Funded Warrants ”), which represents the per share price for the Shares less the $0.0001 per share exercise price for each Pre-Funded Warrant (the “ Offering ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312523043040/0001193125-23-043040-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.